Search results
Added:
1 year ago
ACC.23/WCC—We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C)…
View more
Added:
3 years ago
The primary goal in the treatment of hypertensive patients is to achieve the maximum possible reduction in the long-term total risk of cardiovascular (CV) and renal morbidity and mortality. In addition to the lowering of blood pressure (BP) per se, successful realisation of the primary goal of treatment also requires appropriate consideration of co-morbidities.1–3 Although there is some…
View more
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide.1 The relationship between coronary heart disease (CHD) and elevated low-density lipoprotein cholesterol (LDL-C) levels is well established.2 Several large-scale trials, in both primary and secondary prevention settings, have shown that lowering LDL-C levels using statins substantially reduces cardiovascular…
View more
Added:
2 years ago
In this short late-breaking interview, Prof Felix Mahfoud (Saarland University Hospital, DE) discusses the 3-year efficacy outcomes of the SPYRAL HTN-ON MED Pilot Study (NCT02439775). The global clinical study, presented at ACC.22, tested the long-term effect of renal denervation (Symplicity Spyral™ multi-electrode renal denervation system, Medtronic Vascular) on blood pressure reduction in…
View more
Added:
1 year ago
EASD 22 — Dr Ambarish Pandey (UT Southwestern Medical Center, US) talks about the post-hoc analyses of VERTIS CV trial.
In VERTIS CV, an SGLT2 inhibitor, ertugliflozin (Merck Sharp & Dohme LLC) reduced risk of hospitalization for heart failure compared with placebo. This post-hoc analyses investigated the efficacy of the treatment across the spectrum of ejection fractions (EF) in heart failure.
…
View more
Added:
5 months ago
AHA 23 - We are joined on-site by Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) to discuss the findings from a sub-analysis of the ECLS-SHOCK trial.This sub-analysis investigates the impact of cardiac arrest before randomisation on the efficacy of ECLS in patients with infarct-related cardiogenic shock. Investigators enrolled 420 patients with acute MI and cardiogenic shock across 41…
View more
Added:
5 months ago
A single centre, prospective, non-randomised study from DrDaniela Trabattoni (Monzino Cardiology Centre,Milan, IT) following device implantation of the Occlutech PFO Closure device in 442 consecutive patients.The study is particularly interesting due to the scarcity of data available on the long term follow up (over 5 years after) of device implantation. Also, the results are focussed not only…
View more
Added:
1 year ago
Start date:
Aug 28, 2017
ESC Congress 2017, Barcelona
Discussants: Dr. Dominic Angiolillo (Jacksonville, US) & Prof. Christoph Varenhorst (Uppsala, SE)
An expert peer-to-peer discussion on the latest data to come out of the PEGASUS-TIMI 54 trial and its implications for clinical practice.
View more
